Real World Evidence Solutions Market (By Component: Services, Datasets; By Application: Drug Development & Approvals; By End-user; By Therapeutic Area)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Real World Evidence Solutions Market 

5.1. COVID-19 Landscape: Real World Evidence Solutions Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Real World Evidence Solutions Market, By Component

8.1. Real World Evidence Solutions Market, by Component, 2023-2032

8.1.1. Services

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Data Sets

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Real World Evidence Solutions Market, By Application

9.1. Real World Evidence Solutions Market, by Application, 2023-2032

9.1.1. Drug Development & Approvals

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Medical Device Development & Approvals

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Reimbursement/Coverage & Regulatory Decision Making

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Post Market Safety & Adverse Events Monitoring

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Real World Evidence Solutions Market, By End-user 

10.1. Real World Evidence Solutions Market, by End-user, 2023-2032

10.1.1. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Healthcare Payers

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Healthcare Providers

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Real World Evidence Solutions Market, By Therapeutic Area 

11.1. Real World Evidence Solutions Market, by Therapeutic Area, 2023-2032

11.1.1. Oncology

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Cardiology

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Neurology

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Diabetes

11.1.4.1. Market Revenue and Forecast (2020-2032)

11.1.5. Psychiatry

11.1.5.1. Market Revenue and Forecast (2020-2032)

11.1.6. Respiratory

11.1.6.1. Market Revenue and Forecast (2020-2032)

11.1.7. Other therapeutic areas (Immunology, Gastroenterology, etc.)

11.1.7.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Real World Evidence Solutions Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Component (2020-2032)

12.1.2. Market Revenue and Forecast, by Application (2020-2032)

12.1.3. Market Revenue and Forecast, by End-user (2020-2032)

12.1.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.1.5.3. Market Revenue and Forecast, by End-user (2020-2032)

12.1.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)

12.1.6.3. Market Revenue and Forecast, by End-user (2020-2032)

12.1.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.2. Market Revenue and Forecast, by Application (2020-2032)

12.2.3. Market Revenue and Forecast, by End-user (2020-2032)

12.2.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.2.5.3. Market Revenue and Forecast, by End-user (2020-2032)

12.2.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)

12.2.6.3. Market Revenue and Forecast, by End-user (2020-2032)

12.2.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)

12.2.7.3. Market Revenue and Forecast, by End-user (2020-2032)

12.2.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Component (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)

12.2.8.3. Market Revenue and Forecast, by End-user (2020-2032)

12.2.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.2. Market Revenue and Forecast, by Application (2020-2032)

12.3.3. Market Revenue and Forecast, by End-user (2020-2032)

12.3.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.3.5.3. Market Revenue and Forecast, by End-user (2020-2032)

12.3.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)

12.3.6.3. Market Revenue and Forecast, by End-user (2020-2032)

12.3.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)

12.3.7.3. Market Revenue and Forecast, by End-user (2020-2032)

12.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Component (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)

12.3.8.3. Market Revenue and Forecast, by End-user (2020-2032)

12.3.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.2. Market Revenue and Forecast, by Application (2020-2032)

12.4.3. Market Revenue and Forecast, by End-user (2020-2032)

12.4.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.4.5.3. Market Revenue and Forecast, by End-user (2020-2032)

12.4.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)

12.4.6.3. Market Revenue and Forecast, by End-user (2020-2032)

12.4.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)

12.4.7.3. Market Revenue and Forecast, by End-user (2020-2032)

12.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Component (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)

12.4.8.3. Market Revenue and Forecast, by End-user (2020-2032)

12.4.8.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.5.3. Market Revenue and Forecast, by End-user (2020-2032)

12.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Component (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.5.5.3. Market Revenue and Forecast, by End-user (2020-2032)

12.5.5.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Component (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)

12.5.6.3. Market Revenue and Forecast, by End-user (2020-2032)

12.5.6.4. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

Chapter 13. Company Profiles

13.1. IQVIA

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. IBM

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. PPD Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Parexel International Corporation

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. PerkinElmer Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Icon Plc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Oracle

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Syneos Health

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Cegedim Health Data

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Medpace

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Frequently Asked Questions

The global real world evidence solutions market size was reached at USD 42.45 billion in 2022 and it is projected to hit around USD 93.88 billion by 2032.

The global real world evidence solutions market is growing at a compound annual growth rate (CAGR) of 8.26% from 2023 to 2032.

The North America region has accounted for the largest real world evidence solutions market share in 2022.

Report Details

  • Report Code:39021
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:February 2023
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers